Skip to main content

Table 2 Mortality rate and hazard ratios with 95% CIs of total mortality in relation to CMDs status

From: Cardiometabolic diseases, total mortality, and benefits of adherence to a healthy lifestyle: a 13-year prospective UK Biobank study

CMDs status

Events

Person-years

Mortality rate per 1000 person-year

Hazard ratio (95% CI)

Model 1b

Model 2 c

No

16,287

4,055,268

4.0 (3.9–4.1)

1 (Ref.)

1 (Ref.)

Yes

5186

404,587

12.8 (12.5–13.2)

1.57 (1.51–1.64)

1.56 (1.50–1.63)

Only one

4152

361,739

11.5 (11.1–11.8)

1.50 (1.44–1.56)

1.49 (1.43–1.56)

 Diabetes

1655

154,457

10.7 (10.2–11.2)

1.50 (1.41–1.59)

1.48 (1.40–1.57)

 Stroke

561

51,280

10.9 (10.1–11.9)

1.56 (1.43–1.70)

1.52 (1.40–1.66)

 CHD

1936

156,002

12.4 (11.9–13.0)

1.48 (1.41–1.57)

1.49 (1.41–1.58)

Any two

940

40,809

23.0 (21.6–24.5)

2.19 (2.03–2.36)

2.17 (2.01–2.34)

 CHD & stroke

175

8088

21.6 (18.0–26.1)

2.13 (1.83–2.48)

2.11 (1.81–2.45)

 Diabetes & stroke

112

5167

21.7 (18.0–26.1)

2.17 (1.80–2.62)

2.15 (1.78–2.60)

 Diabetes & CHD

653

27,553

23.7 (21.9–25.6)

2.20 (2.01–2.41)

2.20 (2.01–2.40)

Three (Diabetes & CHD & stroke)

94

2040

46.1 (37.6–56.4)

3.90 (3.17–4.80)

3.75 (3.04–4.61)

P for trend a

   

 < 0.001

 < 0.001

  1. CHD, coronary heart disease; CMD, cardiometabolic disease
  2. aP value of linear trend was calculated by included the number of CMDs as a continuous variable in the model
  3. bModel 1 adjusted for age, sex, ethnicity, Townsend deprivation index, qualifications, employment, cholesterol, C-reactive protein, triglycerides, hypertension, use of aspirin, and use of insulin
  4. cModel 2 further adjusted for lifestyle